Skip to main content

Advertisement

Table 1 IC50s for mifepristone and IC50s for cisplatin in various ovarian cancer cell lines of different p53 genetic backgrounds and platinum sensitivities.

From: Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity

Cell line IC50 MF (μM) IC50CDDP (μM) Reported p53 status
OV2008 8.8 ± 0.8 (5) 0.2 ± 0.1 (3) wt [30]
OV2008/C13 8.1 ± 0.6 (3) 49.8 ± 10 (3) wt [30, 38]
A2780 5.9 ± 0.6 (3) 6.0 ± 1.3 (3) wt [39, 40, 52]
A2780/CP70 11.7 ± 0.6 (3)* 55.0 ± 11 (3) mut [30, 3840]
SK-OV-3 12.6 ± 0.1 (3)* 18.1 ± 0.6 (3) mut [31, 33, 34]
Caov-3 7.4 ± 1.8 (3) 15.2 ± 1.4 (3) mut [31, 32]
  1. Cells were treated with mifepristone (MF) or cisplatin (CDDP) as described in Figure 1A and 1C, Figure 3A and 3C, and Figure 5A, to calculate the concentration of the drugs needed to achieve 50% growth inhibition (IC50). The experiments were repeated at least three times with different cellular passages, each time in triplicates. The numbers in parentheses indicate the number of experiments carried out for each cell line. IC50s are expressed as the mean ± SEM. *p < 0.05 compared with the other cell lines treated with mifepristone. The numbers in brackets indicate references that reported the p53 genetic status of the depicted cell lines.